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ARTICLE
Long-term pretreatment with desethylamiodarone (DEA) or
amiodarone (AMIO) protects against coronary artery occlusion
induced ventricular arrhythmias in conscious rats1
Nikolett Morvay, István Baczkó, Anita Sztojkov-Ivanov, György Falkay, Julius Gy. Papp, András Varró,
and István Leprán
Abstract: The aimof this investigationwas to compare the effectiveness of long-termpretreatmentwith amiodarone (AMIO) and
its active metabolite desethylamiodarone (DEA) on arrhythmias induced by acute myocardial infarction in rats. Acute myocar-
dial infarction was induced in conscious, male, Sprague–Dawley rats by pulling a previously inserted loose silk loop around the
left main coronary artery. Long-term oral pretreatment with AMIO (30 or 100 mg·(kg body mass)−1·day−1, loading dose 100 or
300mg·kg−1 for 3 days) or DEA (15 or 50mg·kg−1·day−1, loading dose 100 or 300mg·kg−1 for 3 days), was applied for 1month before
the coronary artery occlusion. Chronic oral treatment with DEA (50 mg·kg−1·day−1) resulted in a similar myocardial DEA
concentration as chronic AMIO treatment (100 mg·kg−1·day−1) in rats (7.4 ± 0.7 g·g−1 and 8.9 ± 2.2 g·g−1). Both pretreatments in
the larger doses signiﬁcantly improved the survival rate during the acute phase of experimental myocardial infarction (82% and
64% by AMIO and DEA, respectively, vs. 31% in controls). Our results demonstrate that chronic oral treatment with DEA resulted
in similar cardiac tissue levels to that of chronic AMIO treatment, and offered an equivalent degree of antiarrhythmic effect
against acute coronary artery ligation induced ventricular arrhythmias in conscious rats.
Key words: arrhythmias, survival, myocardial infarction, rats, amiodarone, desethylamiodarone.
Résumé : Les présents travaux de recherche avaient pour objectif de comparer l’efﬁcacité d’un prétraitement a` long terme par
l’amiodarone et la déséthylamiodarone, sonmétabolite actif, sur les arythmies induites par l’infarctus aigu dumyocarde chez le
rat. L’infarctus aigu du myocarde a été provoqué chez des rats Sprague–Dawley mâles en appliquant une traction sur une soie
placée au préalable autour de l’artère interventriculaire antérieure. Les prétraitements a` long terme par l’amiodarone (30 ou
100mg·(kg demasse corporelle)−1·jour−1, dose d’attaque de 100 ou de 300mg·kg−1 pendant 3 jours) ou par la déséthylamiodarone
(15 ou 50mg·kg−1·jour−1, dose d’attaque de 100 ou de 300mg·kg−1 pendant 3 jours) ont été administrés par voie orale tout au long
dumois précédant l’occlusion coronarienne. Le traitement chronique par l’administration de déséthylamiodarone par voie orale
(a` 50 mg·kg−1·jour−1) a permis d’obtenir des concentrations similaires de déséthylamiodarone a` celles obtenues par l’administration
chronique d’amiodarone (a` 100mg·kg−1·jour−1) chez les rats (7,4 ± 0,7g·g−1 et 8,9 ± 2,2g·g−1). Aux doses élevées, les deux traitements
ont amélioré le taux de survie pendant la phase aiguë de l’infarctus du myocarde provoqué expérimentalement (82 et 64 % avec
l’amiodarone et la déséthylamiodarone, respectivement p/r a` 31 % dans le groupe témoin). Les résultats cette étude montrent que
l’administrations chronique de déséthylamiodarone ou d’amiodarone par voie orale a permis d’obtenir des concentrations similaires
de déséthylamiodarone dans le tissu cardiaque et des effets de degrés similaires contre les arythmies ventriculaires induites par
l’occlusion coronarienne aiguë chez des rats a` l’état conscient. [Traduit par la Rédaction]
Mots-clés : arythmies, survie, infarctus du myocarde, rats, amiodarone, déséthylamiodarone.
Introduction
Cardiovascular diseases are the leading causes of death in de-
veloped countries, and arrhythmias are common complications
of cardiovascular diseases. Antiarrhythmic drugs today are recom-
mended as an adjuvant treatment to patients receiving an im-
plantable cardioverter deﬁbrillator (ICD) for the prevention and
treatment of ventricular arrhythmias (for a recent review see Bunch
and Anderson 2014).
Chronic treatment with amiodarone (AMIO) is the most effec-
tive pharmacologic tool for treating arrhythmias, with less proar-
rhythmic risk than other antiarrhythmic drugs. Both dofetilide
and d-sotalol (selective IKr blockers) can provoke Torsade de Pointes
(TdP) arrhythmias with an incidence of approximately 3%. AMIO
in this respect is better tolerated, having a proarrhythmic inci-
dence of less than 1% (Doval et al. 1994; Singh et al. 1995; Waldo
et al. 1996; Torp-Pedersen et al. 1999). This effect of AMIO has been
attributed to its sodium channel blocking properties and beta
adrenoceptor blocking effects, leading to decreased dispersion of
repolarization and triggered activity, despite the fact that AMIO
prolongs repolarization by inhibiting a number of different car-
diac potassium channels. In addition, the sodium channel block
caused by AMIO is different compared with those selective Class
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I/C sodium channel blockers ﬂecainide and encainide, whichwere
proven to be proarrhythmic (The Cardiac Arrhythmia Suppression
Trial (CAST) Investigators 1989). AMIO has Class I/B sodium channel
blocking activity, leading to effectively blocked sodium channels
at high frequency and (or) in case early extrasystoles develop. The
calcium channel blocking property of AMIO also contributes to
decreased triggered activity following its administration. In addi-
tion, experimental studies also support the hypothesis that selec-
tive Class III agents cause signiﬁcantly higher incidence of TdP
compared with AMIO (Farkas et al. 2002; Thomsen et al. 2004).
However, AMIO exerts serious extracardiac adverse effects, e.g.,
pulmonary ﬁbrosis, hepatotoxicity, photodermatosis, and cornea
deposits (Tisdale et al. 1995). The unique pharmacokinetic proper-
ties of AMIO (which include an extremely long elimination half-
life as well as its metabolic interactions with several other drugs)
may also contribute to the problems during its long-term use.
AMIO is a representative of Class III antiarrhythmic drugs, with
multiple electrophysiological effects, inhibiting various cardiac
voltage dependent potassium-, sodium-, and calcium-channels, as
well as a reduced -adrenoceptor response in the heart (reviewed
by Kodama et al. 1999). Acute and long-term AMIO treatment inﬂu-
ences transmembrane ionic currents in ventricular myocytes differ-
ently. After acute administration, the sodium and calcium channel
blocking properties dominate, whereas after long-term use, the in-
ward rectifying potassium channel and the transient outward potas-
sium current (Ito) are depressed, with reduced inhibition of the
inward calcium current (Varró et al. 1985, 1996; reviewed by Kodama
et al. 1999).
During chronic AMIO treatment, an electrophysiologically
active metabolite, desethylamiodarone (DEA; 2-N-butyl-3-(3,5-diiodo-
4-ethylaminoethoxy-benzoyl)-benzofuran), is produced and accumu-
lates in the plasma and tissues, including themyocardium (Flanagan
et al. 1982).
DEA produces very similar pharmacological effects when com-
pared with AMIO. Acute administration of both the AMIO and
DEA signiﬁcantly prolonged the QRS, QT, and QTc intervals of the
electrocardiogram in rats. DEA showed a signiﬁcantly greater po-
tency in this respect (Nattel 1986). Acute treatment with either
AMIO or DEA suppressed ventricular arrhythmias after a 2-stage
coronary artery ligation in dogs (Nattel et al. 1988). Long-termadmin-
istration of AMIO or DEA in rabbits prolonged the action potential
duration and the effective refractory period (Kato et al. 1988).
There are some in vivo and ex vivo electrophysiological investiga-
tionson theeffect of long-termdesethylamiodarone treatment; how-
ever, there are no data available comparing long-term treatment
with amiodarone and desethylamiodarone on arrhythmias in ex-
perimental animals, in vivo. Therefore the aim of this investiga-
tion was to compare the effectiveness of long-term pretreatment
with AMIO and its metabolite DEA on ventricular arrhythmias
induced by acute coronary artery occlusion in conscious rats. We
also measured the plasma andmyocardial concentration of AMIO
and DEA after the long-term pretreatments.
Materials and methods
This study protocol was approved by the local animal care com-
mittee of the University of Szeged and conforms with the Guide for
the Care and Use of Laboratory Animals (NAC 2011).
Animals
MaleCFY (remote Sprague–Dawley) rats, weighing 260–300 gwere
used. The animals were housed 5 per cage andweremaintained on a
12 h (light) – 12 h (dark) cycle. The animals were fed standard labora-
tory rat food and allowed to drink tap water ad libitum.
Coronary artery ligation induced arrhythmias in conscious
rats
Coronary artery occlusion in conscious rats was performed as
described earlier (Leprán et al. 1983). In a preliminary surgery,
under ether anesthesia, the chest was opened in the 4th intercos-
tal space. A loose silk loop (5-0; Ethicon) was applied around the
left main coronary artery, and then the chest was closed. Seven to
8 days after the preliminary surgery, and after complete recovery
and healing, the loose silk loop was tightened to occlude the
coronary artery in conscious, freely-moving animals. During the
ﬁrst 15 min of myocardial infarction a bipolar ECG was recorded
continuously (PowerLab 8SP; ADInstruments).
We followed the survival rate during the acute phase (ﬁrst 15min)
and during the following 16 h after coronary artery occlusion. The
incidence and duration of arrhythmias in the acute phase were eval-
uated according to the LambethConventions (Walker et al. 1988), i.e.,
ventricular ﬁbrillation, ventricular tachycardia, and other types of
arrhythmias, including ventricular extrasystoles, bigeminia, and sal-
vos. An arrhythmia score was used, including the incidence and du-
ration of different arrhythmias by giving a grade to each animal as
follows: 0 = no arrhythmia; 1 = <10 s ventricular ectopic beats (VEB),
bigeminia, salvos, and (or) ventricular tachycardia (VT); 2 = 11–30 s
VEB, bigeminia, salvos, and (or) VT; 3 = 31–90 s VEB, bigeminia, sal-
vos, and (or) VT; 4 = 91–180 s VEB, bigeminia, salvos, and (or) VT; <10 s
reversible VF; 5 = >180 s VEB, bigeminia, salvos, and (or) VT; >10 s
reversible VF; 6 = irreversible VF. The size of the myocardial infarc-
tion was measured in the animals surviving for 16 h after coronary
artery occlusion using nitrotetrazolium-blue dye staining to demon-
strate the appropriate production ofmyocardial infarction. Animals
with a scar tissue area of <5% were excluded from the ﬁnal evalua-
tions.
Determination of the plasma and tissue concentration of
AMIO and DEA
At the end of the feeding experiments, the animals were anes-
thetized with pentobarbitone (60 mg·(kg body mass)−1, by intra-
peritoneal (i.p.) injection; Sigma), then blood was taken from the
abdominal aorta and the heart was excised. The ventricular myo-
cardiumwas homogenized, with a tissue blender, in a 0.01mol·L−1
mixture of KH2PO4 (pH = 4.3) andmethanol (75:25; 1:4w/v). Plasma
and tissue homogenates were stored at −70 °C until later analysis.
AMIO and DEA was determined according to the methods of
Bolderman et al. (2009) using an HPLC apparatus (Shimadzu Cor-
Table 1. Inﬂuence of long-term amiodarone (AMIO) or desethyl-
amiodarone (DEA) pretreatment on the heart rate 5 min before
(Baseline) and after coronary artery occlusion in conscious rats.
Time after coronary
artery occlusion (min)
Group Baseline 1 3 5 7 10 12 15
Vehicle
Mean 327 402 395 394 390 380 382 370
SE 5.3 9.4 7.5 8.9 11.7 15.5 15.1 11.2
n 39 37 36 26 12 12 12 12
AMIO 30 mg·kg−1
Mean 343 415 401 385 393 360 364 382
SE 8.1 12.7 17.4 14.7 17.7 21.3 18.9 23.4
n 23 23 19 15 9 9 9 9
AMIO 100 mg·kg−1
Mean 321 373 363 356 365 357 348 340
SE 5.1 12.2 12.9 13.8 9.9 12.1 9.3 7.9
n 22 22 22 17 17 17 18 18
DEA 15 mg·kg−1
Mean 343 420 400 397 410 393 386 375
SE 7.9 15.7 14.9 14.8 16.1 11.9 13.2 12.0
n 23 21 20 15 8 8 8 8
DEA 50 mg·kg−1
Mean 330 398 382 369 365 363 359 350
SE 8.9 11.4 10.3 9.9 8.5 10.8 9.4 6.2
n 22 21 22 18 15 15 14 14
Note: Values are mean ± SE of n animals at the given time point.
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poration, Kyoto, Japan) equipped with a Kromasil Eternity C18
(5 m, 150 mm × 4.6 mm) analytical column (AkzoNobel, Bohus,
Sweden).
Pretreatment
Long-term oral pretreatment was applied for 1 month before
the coronary artery occlusion. The animals were treated orally by
gavage, and the last treatment was given 4 h before the coronary
artery occlusion. The applied doses were as follows: AMIO (Se-
quoia Research Products, Pangbourne, UK) 30 or 100mg·kg−1·day−1
(loading dose 100 or 300 mg·kg−1 for 3 days); DEA (Szintekon, Debre-
cen,Hungary) 15or 50mg·kg−1·day−1 (loadingdose 100or300mg·kg−1
for 3 days). Control animals were given the vehicle in a volume of
5 mL·kg−1. The doses of AMIO were based on ﬁndings of Hu et al.
(2004), and that of DEA on the ﬁndings of Varró et al. (1987).
Statistical analysis
The survival rate was compared by using the 2-method with
Yates correction. All other parameters are expressed as the mean ±
SEM, and after analysis of variance (ANOVA) were compared by
means of the modiﬁed t test (Wallenstein et al. 1980).
Results
Neither AMIO nor DEA administration produced any visible
behavioral changes of the animals during the long-term treat-
ment, or any difference in the gaining of body mass.
There were no signiﬁcant differences in the baseline heart rate
before coronary artery occlusion, or the heart rate response after
coronary artery occlusion among the control and AMIO- or DEA-
treated animals (Table 1). The basal heart rate in our experiments
at the end of the pretreatment period, before coronary ligation in
non-stressed, conscious animals was relatively low (mean values
in the different groups are between 321–343 beats·min−1), and
signiﬁcantly elevated after coronary artery occlusion. This eleva-
tion was smaller in the AMIO- or DEA-treated animals (at 3 min
after occlusion 68, 42, and 52 beats·min−1 in the vehicle, AMIO
100 mg·kg−1, and DEA 50 mg·kg−1 treatment groups, respectively).
Coronary artery occlusion in conscious rats within 4–6 min
resulted in various arrhythmias, frequently leading to irreversible
ventricular ﬁbrillation of the control animals. Both of the pretreat-
ments, in the larger doses, signiﬁcantly improved the survival rate
during the acute phase of experimental myocardial infarction
(Table 2). Signiﬁcantly fewer animals developed ventricular ﬁbril-
lation or tachycardia. Moreover, some animals did not develop
arrhythmia during the ﬁrst 15 min after coronary artery occlusion,
despite the characteristic ECG changes and developing myocardial
damage 16 h later. Bradycardia and atrioventricular-blockade devel-
oped in some animals transiently, after coronary artery occlusion in
the animals treated with AMIO at 30mg·kg−1. The arrhythmia score,
representing the incidence and duration of various arrhythmias and
the survival as a single number, also signiﬁcantly decreased after
pretreatment with the larger doses of AMIO and DEA (Table 2). The
time-lag to the appearance of the ﬁrst arrhythmias was signiﬁcantly
delayed by the larger doses of both pretreatments. On the other
hand, the mean duration of the arrhythmic attacks in the surviving
animals did not change signiﬁcantly (Table 3).
The infarct size was measured in the animals surviving for 16 h
after coronary artery ligation. We could not measure the size of
damage during the acute phase of myocardial infarction, which
is when most of the deaths occurred. The infarct size ranged be-
tween 20.7% ± 5.48% and 22.9% ± 3.83% in the DEA- and vehicle-
treated animals, respectively. There were no signiﬁcant differences
in infarct size among the groups we investigated, and no correlation
was observed between the severity of arrhythmias during the ﬁrst
15 min and infarct size measured 16 h later.
At the end of the pretreatments we also determined the concen-
tration of AMIO and DEA in the plasma and the myocardium.
After AMIO (100 mg·kg−1·day−1), the plasma concentration of its
metabolite (i.e., DEA) was about 1/4 that of the parent molecule
(AMIO). In themyocardium, the tissue concentration of AMIOwas
signiﬁcantly higher (about 10-fold, P < 0.05) than in the plasma,
and itsmainmetabolite, DEA, was at the same high level (Table 4).
Chronic oral administration of DEA (50mg·kg−1·day−1) produced a
concentration of myocardial DEA (7.4 ± 0.7 g·g−1) similar to that
measured after AMIO (100 mg·kg−1) pretreatment.
Discussion
Anesthetized animal models with acute surgical intervention
are commonly used for the investigation of the acute phase of
myocardial infarction. In such conditions the anesthetic agent,
artiﬁcial ventilation, and the acute surgery may greatly and vari-
ably inﬂuence the results (Baczkó et al. 1997). Therefore, it is es-
pecially important to use experimental conditions where the
acute phase of myocardial infarction develops in conscious con-
ditions, as was achieved in our current investigation.
Our experiments demonstrate that after chronic oral treatment
the main metabolite of amiodarone, i.e., desethylamiodarone,
produced antiarrhythmic effects in a rat model of acute coronary
artery ligation induced ventricular arrhythmia that were similar
to its parent compound.
These experiments using long-term treatment with DEA sup-
ports and extends previous investigations in a similar model of
arrhythmia in rats, i.e., acute administration of 50mg·kg−1 deseth-
ylamiodarone, i.p., improved the survival during the ﬁrst 20 min
after coronary artery ligation in rats (Varró et al. 1987). In the
present experiments, DEA in a smaller dose (50mg·kg−1) produced
the same plasma concentration as is measured after the double
dose of AMIO (100 mg·kg−1). This dose of DEA, on the other hand,
offered an antiarrhythmic effect that was comparable with that of
the higher dose of AMIO. The smaller dose of DEA may produce
Table 2. Inﬂuence of long-term amiodarone (AMIO) or desethylamiodarone (DEA) pretreatment on the survival rate and the incidence of
arrhythmias during the ﬁrst 15 min after coronary artery occlusion in conscious rats.
Incidence of arrhythmias
Survived None VF VT Other Br
Survived
for 16 h
Group N n % n % n % n % n % n %
Arrhythmia
score n %
Vehicle 39 12 31 2 5 29 74 35 90 28 72 1 3 4.77±0.33 8 21
AMIO 30 mg·kg−1 23 9 39 1 4 16 70 20 87 13 57 6 26* 4.57±0.43 8 35
AMIO 100 mg·kg−1 22 18 82* 10 45* 5 23* 9 41* 8 36* 2 9 2.05±0.52* 18 82*
DEA 15 mg·kg−1 23 8 39 3 13 16 70 18 78 14 61 3 13 4.35±0.52 4 17
DEA 50 mg·kg−1 22 14 64* 6 27* 10 45* 15 68* 13 59 2 9 3.27±0.56* 12 55*
Note: N, number of animals in the group; n, number of animals showing the given response; None, no arrhythmia occurred; VF, ventricular ﬁbrillation;
VT, ventricular tachycardia; Other, extrasystoles, bigeminia; Br, bradycardia; *, P < 0.05 compared with the vehicle treated group.
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fewer adverse effects as well as less of a problem with drug inter-
actions during long-term use.
Chronic AMIO treatment is the most effective antiarrhythmic
drug treatment today, producing negligible negative inotropic
effect and a very low incidence of proarrhythmia, which is the
major problem with the long-term use of other antiarrhythmic
drugs. On the other hand, the extracardiac adverse effects and
uniquepharmacokinetic properties ofAMIOcreate several problems
during routine use. AMIO is extensively and variably metabolized to
desethylamiodarone in the ﬁrst pass during the absorption. Thema-
jor enzymes responsible for this reaction in human beings are the
cytochrome P450 1A1, 3A4, and 1A2 isoenzymes (Elsherbiny et al.
2008). AMIO and DEA are further metabolized by dealkylation,
hydroxylation, and deamination in human beings (Ha et al. 2001).
Enzyme polymorphism, as well as the co-administration of en-
zyme inhibitors or inducers, greatly inﬂuence the rate of conver-
sion of amiodarone, and are responsible for the great individual
variations in response and for the interactionswith other drugs or
food (Heimark et al. 1992; Libersa et al. 2000; Werner et al. 2004;
Becquemont et al. 2007).
Our results demonstrate that the antiarrhythmic effect of DEA
after chronic oral treatment was achieved with similar plasma
and tissue levels of DEA, without however, the presence of the
relatively high levels of AMIO that occurred during the double
dose of AMIO during the chronic treatment.
These results also support the hypothesis that during long-term
administration, amiodarone undergoes signiﬁcant metabolism,
and its mainmetabolite, desethylamiodarone, accumulates in the
myocardium and may contribute to the antiarrhythmic effect.
This ﬁnding may also suggest the long-term use of DEA instead of
AMIO as an antiarrhythmic tool in human beings. Since the adverse
effects of chronic AMIO therapy presumably depend on tissue accu-
mulation of the drug in various organs, it could be expected that
substituting DEA for AMIO in clinical practice would result in a bet-
ter therapeutic option, resulting in similar effectiveness with less of
the limiting drug toxicity. Using the active metabolite of AMIO, i.e.,
DEA, may exclude individual variations in the metabolism of AMIO
to DEA, as well as the interaction of this metabolic reaction with
other drugs and food, and may result in a more easily optimized
dosage and fewer adverse effects.
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